

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/006895-2021>

Planning

## **NHS England Specialised Commissioning - Thrombotic Thrombocytopenic Purpura (TTP) all ages (up to 8 Lots)**

NHS England - Specialised Commissioning

F21: Social and other specific services – public contracts

Prior information notice without call for competition

Notice identifier: 2021/S 000-006895

Procurement identifier (OCID): ocids-h6vhtk-02a260

Published 1 April 2021, 6:51pm

### **Section I: Contracting authority**

#### **I.1) Name and addresses**

NHS England - Specialised Commissioning

80 London Road

London

SE1 6LH

#### **Email**

[lisa.innes1@nhs.net](mailto:lisa.innes1@nhs.net)

#### **Country**

United Kingdom

#### **NUTS code**

UK - United Kingdom

**National registration number**

N/A

**Internet address(es)**

Main address

<https://www.england.nhs.uk/commissioning/spec-services/>

Buyer's address

<https://www.ardengemcsu.nhs.uk/>

**I.3) Communication**

The procurement documents are available for unrestricted and full direct access, free of charge, at

<https://uk.eu-supply.com/ctm/supplier/publictenders?B=UK>

Additional information can be obtained from the above-mentioned address

**I.4) Type of the contracting authority**

Body governed by public law

**I.5) Main activity**

Health

---

**Section II: Object**

**II.1) Scope of the procurement**

**II.1.1) Title**

NHS England Specialised Commissioning - Thrombotic Thrombocytopenic Purpura (TTP)  
all ages (up to 8 Lots)

Reference number

NHSSC-TPP-2021-NHS England

**II.1.2) Main CPV code**

- 85100000 - Health services

**II.1.3) Type of contract**

Services

**II.1.4) Short description**

Thrombotic Thrombocytopenic Purpura (TTP) is a serious blood disorder that results in blood clots forming in small blood vessels throughout the body. It affects the kidneys, heart and brain. If a patient is treated outside a specialist centre, mortality is 50%; in a specialist centre, it is 20%. There is also an appreciable acute morbidity, particularly in neurological disorders.

The condition can be difficult to diagnose because initial presentation can be non-specific and this is a very rare disease. Rapid treatment is essential for optimal outcomes and includes plasma exchange and a range of drugs. This disease primarily affects Adults. Children are treated in paediatric haematology centres and are outside the scope of this process.

Please see Section II.3 for complementary information.

**II.1.6) Information about lots**

This contract is divided into lots: Yes

**II.2) Description****II.2.1) Title**

Thrombotic Thrombocytopenic Purpura (TTP) – London and the South East (Kent, Surrey, East & West Sussex)

Lot No

1

**II.2.2) Additional CPV code(s)**

- 85000000 - Health and social work services
- 85100000 - Health services

### **II.2.3) Place of performance**

NUTS codes

- UKJ4 - Kent
- UKJ2 - Surrey, East and West Sussex
- UKI - London

Main site or place of performance

London and the South East (Kent, Surrey, East & West Sussex)

### **II.2.4) Description of the procurement**

Thrombotic Thrombocytopenic Purpura (TTP) is a very rare, complex condition which can present as an acute life-threatening disorder that requires prompt diagnosis, early referral and effective immediate management in a centre with comprehensive provision and a multi-discipline approach. Specialist aftercare is also required. There is also a cohort of patients who have a congenital form of the disease who require ongoing apheresis (where a patient's blood is filtered and then put back into their body). The national prevalence is 330 patients in England, with an acute incidence of 150 patients.

There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are currently 2 centres in England where there are recognised services and where the survival rate is 80%.

NHS Arden & Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of the Commissioner(s), NHS England - Specialised Commissioning, are looking to commission up to a further 8 Centres across England for TTP services and are inviting interested Providers to register their interest for these services. The service is a Schedule 3 Service and is being procured under the Light Touch Regime (LTR) of the Public Contract Regulations 2015.

There are patient flows to London from all over the South East. Commissioners have considered establishing one specialist provider for all of London and the South East and this is the default commissioner position.

Commissioners will consider bids for the South East (Thames Valley and Hampshire and Isle of Wight areas - (Lot 2)), to facilitate patient choice and to reduce the requirement to travel for providers who meet the criteria in the service specification, in the technical questionnaire and who are willing to work within a Clinical Partnership with the successful bidder for the London and South East Lot (Lot 1).

The contracting term for these services will be for a period of up to 4 years. Providers will need to register for the Provider Selection Process which is due to be published Mid-April / early May 2021.

## **II.2) Description**

### **II.2.1) Title**

Thrombotic Thrombocytopenic Purpura (TTP) - South East (Thames Valley, Hampshire and the Isle of Wight)

Lot No

2

### **II.2.2) Additional CPV code(s)**

- 85000000 - Health and social work services
- 85100000 - Health services

### **II.2.3) Place of performance**

NUTS codes

- UKJ - South East (England)

Main site or place of performance

South East (Thames Valley, Hampshire and the Isle of Wight)

### **II.2.4) Description of the procurement**

Thrombotic Thrombocytopenic Purpura (TTP) is a very rare, complex condition which can present as an acute life-threatening disorder that requires prompt diagnosis, early referral and effective immediate management in a centre with comprehensive provision and a multi-discipline approach. Specialist aftercare is also required. There is also a cohort of patients who have a congenital form of the disease who require ongoing apheresis (where a patient's blood is filtered and then put back into their body). The national prevalence is 330 patients in England, with an acute incidence of 150 patients.

There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are currently 2 centres in England where there are recognised services and where the survival rate is 80%.

NHS Arden & Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of

the Commissioner(s), NHS England - Specialised Commissioning, are looking to commission up to a further 8 Centres across England for TTP services and are inviting interested Providers to register their interest for these services. The service is a Schedule 3 Service and is being procured under the Light Touch Regime (LTR) of the Public Contract Regulations 2015.

The contracting term for these services will be for a period of up to 4 years. Providers will need to register for the Provider Selection Process which is due to be published Mid-April / early May 2021.

## **II.2) Description**

### **II.2.1) Title**

Thrombotic Thrombocytopenic Purpura (TTP) - South West

Lot No

3

### **II.2.2) Additional CPV code(s)**

- 85000000 - Health and social work services
- 85100000 - Health services

### **II.2.3) Place of performance**

NUTS codes

- UKK - South West (England)

Main site or place of performance

South West

### **II.2.4) Description of the procurement**

Thrombotic Thrombocytopenic Purpura (TTP) is a very rare, complex condition which can present as an acute life-threatening disorder that requires prompt diagnosis, early referral and effective immediate management in a centre with comprehensive provision and a multi-discipline approach. Specialist aftercare is also required. There is also a cohort of patients who have a congenital form of the disease who require ongoing apheresis (where a patient's blood is filtered and then put back into their body). The national prevalence is 330 patients in England, with an acute incidence of 150 patients.

There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are currently 2 centres in England where there are recognised services and where the survival rate is 80%.

NHS Arden & Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of the Commissioner(s), NHS England - Specialised Commissioning, are looking to commission up to a further 8 Centres across England for TTP services and are inviting interested Providers to register their interest for these services. The service is a Schedule 3 Service and is being procured under the Light Touch Regime (LTR) of the Public Contract Regulations 2015.

The contracting term for these services will be for a period of up to 4 years. Providers will need to register for the Provider Selection Process which is due to be published Mid-April / early May 2021.

## **II.2) Description**

### **II.2.1) Title**

Thrombotic Thrombocytopenic Purpura (TTP) - West Midlands

Lot No

4

### **II.2.2) Additional CPV code(s)**

- 85000000 - Health and social work services
- 85100000 - Health services

### **II.2.3) Place of performance**

NUTS codes

- UKG - West Midlands (England)

Main site or place of performance

West Midlands

### **II.2.4) Description of the procurement**

Thrombotic Thrombocytopenic Purpura (TTP) is a very rare, complex condition which can present as an acute life-threatening disorder that requires prompt diagnosis, early referral and effective immediate management in a centre with comprehensive provision and a

multi-discipline approach. Specialist aftercare is also required. There is also a cohort of patients who have a congenital form of the disease who require ongoing apheresis (where a patient's blood is filtered and then put back into their body). The national prevalence is 330 patients in England, with an acute incidence of 150 patients.

There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are currently 2 centres in England where there are recognised services and where the survival rate is 80%.

NHS Arden & Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of the Commissioner(s), NHS England - Specialised Commissioning, are looking to commission up to a further 8 Centres across England for TTP services and are inviting interested Providers to register their interest for these services. The service is a Schedule 3 Service and is being procured under the Light Touch Regime (LTR) of the Public Contract Regulations 2015.

The contracting term for these services will be for a period of up to 4 years. Providers will need to register for the Provider Selection Process which is due to be published Mid-April / early May 2021.

## **II.2) Description**

### **II.2.1) Title**

Thrombotic Thrombocytopenic Purpura (TTP) - East Midlands

Lot No

5

### **II.2.2) Additional CPV code(s)**

- 85000000 - Health and social work services
- 85100000 - Health services

### **II.2.3) Place of performance**

NUTS codes

- UKF - East Midlands (England)

Main site or place of performance

East Midlands



## **II.2.4) Description of the procurement**

Thrombotic Thrombocytopenic Purpura (TTP) is a very rare, complex condition which can present as an acute life-threatening disorder that requires prompt diagnosis, early referral and effective immediate management in a centre with comprehensive provision and a multi-discipline approach. Specialist aftercare is also required. There is also a cohort of patients who have a congenital form of the disease who require ongoing apheresis (where a patient's blood is filtered and then put back into their body). The national prevalence is 330 patients in England, with an acute incidence of 150 patients.

There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are currently 2 centres in England where there are recognised services and where the survival rate is 80%.

NHS Arden & Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of the Commissioner(s), NHS England - Specialised Commissioning, are looking to commission up to a further 8 Centres across England for TTP services and are inviting interested Providers to register their interest for these services. The service is a Schedule 3 Service and is being procured under the Light Touch Regime (LTR) of the Public Contract Regulations 2015.

The contracting term for these services will be for a period of up to 4 years. Providers will need to register for the Provider Selection Process which is due to be published Mid-April / early May 2021.

## **II.2) Description**

### **II.2.1) Title**

Thrombotic Thrombocytopenic Purpura (TTP) - East of England

Lot No

6

### **II.2.2) Additional CPV code(s)**

- 85000000 - Health and social work services
- 85100000 - Health services

### **II.2.3) Place of performance**

NUTS codes

- UKH - East of England

Main site or place of performance

East of England

#### **II.2.4) Description of the procurement**

Thrombotic Thrombocytopenic Purpura (TTP) is a very rare, complex condition which can present as an acute life-threatening disorder that requires prompt diagnosis, early referral and effective immediate management in a centre with comprehensive provision and a multi-discipline approach. Specialist aftercare is also required. There is also a cohort of patients who have a congenital form of the disease who require ongoing apheresis (where a patient's blood is filtered and then put back into their body). The national prevalence is 330 patients in England, with an acute incidence of 150 patients.

There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are currently 2 centres in England where there are recognised services and where the survival rate is 80%.

NHS Arden & Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of the Commissioner(s), NHS England - Specialised Commissioning, are looking to commission up to a further 8 Centres across England for TTP services and are inviting interested Providers to register their interest for these services. The service is a Schedule 3 Service and is being procured under the Light Touch Regime (LTR) of the Public Contract Regulations 2015.

The contracting term for these services will be for a period of up to 4 years. Providers will need to register for the Provider Selection Process which is due to be published Mid-April / early May 2021.

## **II.2) Description**

### **II.2.1) Title**

Thrombotic Thrombocytopenic Purpura (TTP) - North East

Lot No

7

### **II.2.2) Additional CPV code(s)**

- 85000000 - Health and social work services
- 85100000 - Health services

### **II.2.3) Place of performance**

NUTS codes

- UKC - North East (England)

Main site or place of performance

North East

### **II.2.4) Description of the procurement**

Thrombotic Thrombocytopenic Purpura (TTP) is a very rare, complex condition which can present as an acute life-threatening disorder that requires prompt diagnosis, early referral and effective immediate management in a centre with comprehensive provision and a multi-discipline approach. Specialist aftercare is also required. There is also a cohort of patients who have a congenital form of the disease who require ongoing apheresis (where a patient's blood is filtered and then put back into their body). The national prevalence is 330 patients in England, with an acute incidence of 150 patients.

There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are currently 2 centres in England where there are recognised services and where the survival rate is 80%.

NHS Arden & Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of the Commissioner(s), NHS England - Specialised Commissioning, are looking to commission up to a further 8 Centres across England for TTP services and are inviting interested Providers to register their interest for these services. The service is a Schedule 3 Service and is being procured under the Light Touch Regime (LTR) of the Public Contract Regulations 2015.

The contracting term for these services will be for a period of up to 4 years. Providers will need to register for the Provider Selection Process which is due to be published Mid-April / early May 2021.

## **II.2) Description**

### **II.2.1) Title**

Thrombotic Thrombocytopenic Purpura (TTP) - Yorkshire and the Humber

Lot No

### **II.2.2) Additional CPV code(s)**

- 85000000 - Health and social work services
- 85100000 - Health services

### **II.2.3) Place of performance**

NUTS codes

- UKE - Yorkshire and the Humber

Main site or place of performance

Yorkshire and the Humber

### **II.2.4) Description of the procurement**

Thrombotic Thrombocytopenic Purpura (TTP) is a very rare, complex condition which can present as an acute life-threatening disorder that requires prompt diagnosis, early referral and effective immediate management in a centre with comprehensive provision and a multi-discipline approach. Specialist aftercare is also required. There is also a cohort of patients who have a congenital form of the disease who require ongoing apheresis (where a patient's blood is filtered and then put back into their body). The national prevalence is 330 patients in England, with an acute incidence of 150 patients.

There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are currently 2 centres in England where there are recognised services and where the survival rate is 80%.

NHS Arden & Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of the Commissioner(s), NHS England - Specialised Commissioning, are looking to commission up to a further 8 Centres across England for TTP services and are inviting interested Providers to register their interest for these services. The service is a Schedule 3 Service and is being procured under the Light Touch Regime (LTR) of the Public Contract Regulations 2015.

The contracting term for these services will be for a period of up to 4 years. Providers will need to register for the Provider Selection Process which is due to be published Mid-April / early May 2021.

### **II.3) Estimated date of publication of contract notice**

4 May 2021

---

## Section VI. Complementary information

### VI.3) Additional information

In response to a recommendation from the Prescribed Specialised Services Advisory Group in 2014, NHS England developed a service model that aimed to balance the high levels of multi-disciplinary expertise required to treat patients with TTP with the requirement for patients to be treated rapidly to have optimal outcomes. NHS England undertook a public consultation on the draft service specification, which closed in October 2018. The consultation documents are still available on the NHS England website at this link:

Consultation on service specifications for thrombotic thrombocytopenic purpura (TTP) for all ages - NHS England - Citizen Space.

The model of delivery is to offer in-patient care within a specialist TTP centre, Patients with TTP require lifelong monitoring and follow up to manage relapse. Shared care is possible, based on the preference of the patient. Specialist TTP centres are required to undertake a clinical leadership, proactive education and outreach service to hospitals within their region to improve the identification of patients with TTP and the timely referral of patients to the specialist TTP centres.

Specialist TTP centres are required to establish robust clinical partnerships with paediatric haematology centres to provide support in relation to the treatment of children and to agree a transition policy.

There are patient flows to London from all over the South East. Commissioners have considered establishing one provider for all of London and the South East and this is the default Commissioner position.

Commissioners will consider bids for the South East (Thames Valley and Hampshire and Isle of Wight areas, (Lot 2)) to facilitate patient choice and to reduce the requirement to travel for providers who meet the criteria in the service specification, in the technical questionnaire and who are willing to work within a Clinical Partnership with the successful bidder for the London and South East Lot (Lot 1).

This will support effective care and improve local patient access to the service whilst ensuring availability of clinical expertise as appropriate.

Commissioners are planning to publish the Provider Selection process Mid-April / early May 2021. To register your interest in these services please follow this link <https://uk.eu-supply.com/ctm/supplier/publictenders?B=UK> and either login or register on EU Supply and search from ID number 44013.

